{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T01:10:48Z","timestamp":1686273048541},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.cld.2011.05.006","type":"journal-article","created":{"date-parts":[[2011,8,25]],"date-time":"2011-08-25T19:40:21Z","timestamp":1314301221000},"page":"585-596","source":"Crossref","is-referenced-by-count":5,"title":["The HIV\/HCV-Coinfected Patient and New Treatment Options"],"prefix":"10.1016","volume":"15","author":[{"given":"Marie-Louise C.","family":"Vachon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas T.","family":"Dieterich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.cld.2011.05.006_bib1","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/archinte.164.21.2349","article-title":"Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001","volume":"164","author":"Giordano","year":"2004","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.cld.2011.05.006_bib2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1086\/367643","article-title":"Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus","volume":"36","author":"Martinez-Sierra","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.cld.2011.05.006_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.aids.0000198087.47454.e1","article-title":"Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease","volume":"20","author":"Merchante","year":"2006","journal-title":"AIDS"},{"issue":"12","key":"10.1016\/j.cld.2011.05.006_bib4","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1097\/QAD.0b013e32833adbb5","article-title":"Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy","volume":"24","author":"Potter","year":"2010","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.cld.2011.05.006_bib5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jama.288.2.199","article-title":"Hepatitis C and progression of HIV disease","volume":"288","author":"Sulkowski","year":"2002","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.cld.2011.05.006_bib6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/QAI.0b013e318198a0e1","article-title":"Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression","volume":"50","author":"Peters","year":"2009","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"10","key":"10.1016\/j.cld.2011.05.006_bib7","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1097\/QAD.0b013e32833a0918","article-title":"Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study","volume":"24","author":"Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group","year":"2010","journal-title":"AIDS"},{"issue":"15","key":"10.1016\/j.cld.2011.05.006_bib8","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archinte.166.15.1632","article-title":"Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study","volume":"166","author":"Weber","year":"2006","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1016\/j.cld.2011.05.006_bib9","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1086\/644771","article-title":"Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression","volume":"49","author":"Chen","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.cld.2011.05.006_bib10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hep.23020","article-title":"Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus","volume":"50","author":"Berenguer","year":"2009","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.cld.2011.05.006_bib11","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/QAD.0b013e3281084e4d","article-title":"Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel","volume":"21","author":"Soriano","year":"2007","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.cld.2011.05.006_bib12","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/jac\/dkp106","article-title":"Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients","volume":"63","author":"Berenguer","year":"2009","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.cld.2011.05.006_bib13","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2011.05.006_bib14","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.cld.2011.05.006_bib15","doi-asserted-by":"crossref","first-page":"F27","DOI":"10.1097\/00002030-200409030-00003","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV\/HCV co-infected patients","volume":"18","author":"Laguno","year":"2004","journal-title":"AIDS"},{"issue":"23","key":"10.1016\/j.cld.2011.05.006_bib16","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial","volume":"292","author":"Carrat","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.cld.2011.05.006_bib17","unstructured":"Rodriguez-Torres M, Slim J, Lea B. Standard versus high dose ribavirin in combination with peginterferon alfa-2a (40KD) in genotype 1 (G1) HCV patients coinfected with HIV: final results of the PARADIGM study. An Oral Presentation AASLD 60th Meeting, 2009 [abstract: 1561]."},{"issue":"8","key":"10.1016\/j.cld.2011.05.006_bib18","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1089\/aid.2007.0011","article-title":"Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial","volume":"23","author":"Nunez","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"8","key":"10.1016\/j.cld.2011.05.006_bib19","doi-asserted-by":"crossref","first-page":"F23","DOI":"10.1097\/QAD.0b013e3283391d6d","article-title":"Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV\/hepatitis C virus-coinfected patients","volume":"24","author":"Rallon","year":"2010","journal-title":"AIDS"},{"issue":"7262","key":"10.1016\/j.cld.2011.05.006_bib20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.cld.2011.05.006_bib21","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1097\/QAD.0b013e32833eacfd","article-title":"Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV\/hepatitis C virus-coinfected individuals","volume":"24","author":"Rizza","year":"2010","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.cld.2011.05.006_bib22","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/hep.23489","article-title":"Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C","volume":"51","author":"Petta","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2011.05.006_bib23","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jhep.2010.08.036","article-title":"Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy","volume":"54","author":"Lange","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2011.05.006_bib24","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0168-8278(10)60057-8","article-title":"Vitamin D supplement improves SVR in chronic hepatitis C (genotype 1) naive patients treated with pegInterferon and ribavirin","volume":"52","author":"Mouch","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2011.05.006_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1432-2277.2010.01141.x","article-title":"Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C","volume":"24","author":"Bitetto","year":"2011","journal-title":"Transpl Int"},{"issue":"8","key":"10.1016\/j.cld.2011.05.006_bib26","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/QAD.0b013e328337b161","article-title":"High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients","volume":"24","author":"Mueller","year":"2010","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.cld.2011.05.006_bib27","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1089\/aid.2009.0308","article-title":"Short communication: inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users","volume":"26","author":"Childs","year":"2010","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"5","key":"10.1016\/j.cld.2011.05.006_bib28","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/QAD.0b013e3280464db7","article-title":"Hepatitis C virus infection is associated with insulin resistance among older adults with or at risk of HIV infection","volume":"21","author":"Howard","year":"2007","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.cld.2011.05.006_bib29","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1053\/j.gastro.2003.08.032","article-title":"Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]","volume":"125","author":"Hui","year":"2003","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2011.05.006_bib30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hep.20983","article-title":"Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C","volume":"43","author":"Camma","year":"2006","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2011.05.006_bib31","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/hep.22134","article-title":"Steatohepatitis: risk factors and impact on disease severity in human immunodeficiency virus\/hepatitis C virus coinfection","volume":"47","author":"Sterling","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2011.05.006_bib32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/QAI.0b013e318186ede8","article-title":"Insulin resistance is associated with advanced liver fibrosis and high body mass index in HIV\/HCV-coinfected patients","volume":"50","author":"Ryan","year":"2009","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"3","key":"10.1016\/j.cld.2011.05.006_bib33","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/j.gastro.2004.12.049","article-title":"Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients","volume":"128","author":"Romero-Gomez","year":"2005","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cld.2011.05.006_bib34","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1572-0241.2005.41403.x","article-title":"Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy","volume":"100","author":"D'Souza","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2011.05.006_bib35","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3851\/IMP1298","article-title":"Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study","volume":"14","author":"Cacoub","year":"2009","journal-title":"Antivir Ther"},{"issue":"2","key":"10.1016\/j.cld.2011.05.006_bib36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/QAI.0b013e3181e5b1f0","article-title":"Insulin resistance impairs response to interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus","volume":"55","author":"Ryan","year":"2010","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.cld.2011.05.006_bib37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jhep.2010.06.025","article-title":"Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-alpha-2a and ribavirin in HIV\/HCV co-infected patients","volume":"54","author":"Vachon","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2011.05.006_bib38","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2008.10.032","article-title":"Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV\/HCV co-infected patients","volume":"50","author":"Merchante","year":"2009","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2011.05.006_bib39","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/hep.23206","article-title":"Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin","volume":"50","author":"Romero-Gomez","year":"2009","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2011.05.006_bib40","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1478-3231.2009.02171.x","article-title":"Pioglitazone improves virological response to peginterferon alpha-2b\/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance","volume":"30","author":"Khattab","year":"2009","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.cld.2011.05.006_bib41","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jhep.2008.03.033","article-title":"Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin","volume":"49","author":"Overbeck","year":"2008","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2011.05.006_bib42","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/QAI.0b013e31815ac47d","article-title":"Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV\/hepatitis C virus coinfection","volume":"47","author":"Opravil","year":"2008","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"10","key":"10.1016\/j.cld.2011.05.006_bib43","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.cgh.2010.06.019","article-title":"Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection","volume":"8","author":"Farnik","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 4","key":"10.1016\/j.cld.2011.05.006_bib44","first-page":"753A","article-title":"Length of peginterferon-ribavirin therapy according to HCV genotype and rapid virological response in HIV\/HCV coinfected patients: the EXTENT trial","volume":"52","author":"Barreiro","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl 4","key":"10.1016\/j.cld.2011.05.006_bib45","first-page":"82A","article-title":"HCV treatment duration in HIV\/HCV genotype 1 co-infected patients. Results of a multicenter randomized trial","volume":"52","author":"Barone","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl 4","key":"10.1016\/j.cld.2011.05.006_bib46","first-page":"785A","article-title":"72 weeks treatment duration reduces relapse rate in HCV\/HIV co-infected patients with end of treatment response","volume":"52","author":"Brandao-Mello","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2011.05.006_bib47","unstructured":"Vachon ML, Factor S, Sterling RK, et\u00a0al. Peginterferon-a-2b plus weight-based ribavirin for 48 vs 72 weeks in HIV\/HCV co-infected patients: a randomized trial. A Poster Presentation CROI 18th, Meeting. Boston, February 27\u2013March 2, 2011 [abstract: # Q-205]."},{"issue":"4","key":"10.1016\/j.cld.2011.05.006_bib48","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/QAD.0b013e328343443b","article-title":"Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference","volume":"25","author":"The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel","year":"2011","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.cld.2011.05.006_bib49","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/jac\/dkq086","article-title":"New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals","volume":"65","author":"Seden","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.cld.2011.05.006_bib50","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.qai.0000174649.51084.46","article-title":"Risk factors for symptomatic mitochondrial toxicity in HIV\/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy","volume":"40","author":"Bani-Sadr","year":"2005","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"6","key":"10.1016\/j.cld.2011.05.006_bib51","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jac\/dkm373","article-title":"Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus\/HIV-coinfected patients","volume":"60","author":"Pineda","year":"2007","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.cld.2011.05.006_bib52","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/135965350801300303","article-title":"Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir","volume":"13","author":"Vispo","year":"2008","journal-title":"Antivir Ther"},{"issue":"3","key":"10.1016\/j.cld.2011.05.006_bib53","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/095632020701800306","article-title":"Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir","volume":"18","author":"Kempf","year":"2007","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.cld.2011.05.006_bib54","unstructured":"Garg V, Luo X, McNair L, et al. Low-dose RTV and the pharmacokinetics of the investigational HCV protease inhibitor TVR in healthy volunteers. CROI 2011 [abstract: 629]."},{"issue":"Suppl 1","key":"10.1016\/j.cld.2011.05.006_bib55","doi-asserted-by":"crossref","first-page":"S289","DOI":"10.1016\/S0168-8278(10)60745-3","article-title":"Naturally occurring drug resistance mutations in the hepatitis C virus NS3 protease in HIV\/HCV coinfected patients treated with HIV protease inhibitors","volume":"52","author":"Bottecchia","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2011.05.006_bib56","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/591141","article-title":"Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects","volume":"198","author":"Bartels","year":"2008","journal-title":"J\u00a0Infect Dis"},{"issue":"6","key":"10.1016\/j.cld.2011.05.006_bib57","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.22549","article-title":"Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients","volume":"48","author":"Kuntzen","year":"2008","journal-title":"Hepatology"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932611100033X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932611100033X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:36:02Z","timestamp":1686270962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108932611100033X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S108932611100033X"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2011.05.006","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}